DDInter1642 DDInter174
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Belinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Belinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Belinostat {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Belinostat {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Belinostat may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Belinostat may lead to a major life threatening interaction when taken with Leflunomide